Precision BioSciences (DTIL) Expected to Release Earnings on Thursday

Precision BioSciences (NASDAQ:DTIL) is anticipated to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Precision BioSciences to announce earnings of ($0.71) per share and revenue of $1.40 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). The business had revenue of $10.84 million for the quarter, compared to analysts’ expectations of $4.05 million. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 85.37%. On average, analysts expect Precision BioSciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Precision BioSciences Stock Up 1.0%

DTIL opened at $7.06 on Tuesday. Precision BioSciences has a 12 month low of $3.53 and a 12 month high of $9.62. The company has a market cap of $182.15 million, a PE ratio of -1.92 and a beta of 1.27. The company has a current ratio of 14.02, a quick ratio of 14.02 and a debt-to-equity ratio of 0.29. The company has a 50 day moving average of $7.35 and a 200 day moving average of $6.25.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DTIL. Engineers Gate Manager LP purchased a new position in shares of Precision BioSciences during the 4th quarter valued at $43,000. Occudo Quantitative Strategies LP purchased a new position in Precision BioSciences during the fourth quarter worth about $52,000. Virtu Financial LLC bought a new position in Precision BioSciences in the 3rd quarter worth about $84,000. Velan Capital Investment Management LP bought a new position in Precision BioSciences in the 3rd quarter worth about $110,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Precision BioSciences in the 3rd quarter valued at about $122,000. 37.99% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on DTIL shares. JonesTrading restated a “buy” rating and set a $30.00 target price on shares of Precision BioSciences in a research report on Friday, April 17th. HC Wainwright reiterated a “buy” rating on shares of Precision BioSciences in a research report on Monday. Weiss Ratings upgraded Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. Finally, Oppenheimer assumed coverage on Precision BioSciences in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $20.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.25.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.